Dr. Musa Providence Swedish Providence Swedish Cancer Institute Research contributes to SGO summit report on the future of gyn-onc pubmed.ncbi.nlm.nih.gov/36827841/

Way to go Annie Ellis patient advocate speaking at a Scientific Plenary session Long-term survivors speak: patient perspectives on progress #SGOMtg #PatientsPurposeProgress #gyncsm

Honored to report the final results of #GOG 258 @SGOmtg. Addition of radiation to chemotherapy does not improve overall survival for stage III #endometrialcancer. Lurie Cancer Center #NorthwesternMed.

LBA happening now! ⁦Ramez Eskander⁩ and Dr. Mirza about to present GY-O18 and RUBY #sgo2023 and change the frontline treatment of endometrial cancer Meshal ⁦The GOG Foundation Inc.⁩ ⁦GYN Cancer | #GYNCSM⁩ ACOG @asco

🧐 How were they different?? rebecca arend distills the details of RUBY and GY018. Bottom line - practice changing for #EndometrialCancer + great representation of typically underrepresented minority volunteers == A HOME RUN! #SGOMtg #gyncsm #ImmunoOnc

Endometrial cancer patient Sarah Greene thanks SGO for all the hard work. Standing ovation!! #SGOmtg #PatientsPurposeProgress #gyncsm

It's a great day for #GynOnc research, with new findings showing significant progression-free survival improvement for some #immunotherapy/chemo combos. Here's a look at one study focusing on advanced endometrial cancer, conducted in part by the The James' Floor Backes. (1/2)

Congrats Dr. Musa and the Providence Swedish Cancer Institute Research Providence Swedish on your contributions to this practice changing study!

Dr Sarah Lee: Gynecologic cancer trends by disaggregated Asian American and Native Hawaiian/Pacific Islander groups: A National Cancer Database Analysis #SGOmtg #gyncsm #PatientsPurposeProgress More work needed to disaggregate!

Congratulations to Angeles Secord on her award for 2022 Best Clinical Practice Abstract (presented at the 2023 SGO Annual Meeting) and for her new role as president of SGO! #WomensHistoryMonth #NationalDoctorsDay

Celebrating 25 years of AACR’s Scientist↔️Survivor Program! Bringing together patients, patient advocates and researchers. #AACRSSP #AACR23 Encouraging partnerships and collaborations to infuse science with patient perspectives and empower advocates to engage in research.

Please join us as we discuss strategies to optimize care for our pts and support providers during this challenging time of chemo shortages. Grateful for wonderful, expert webinar colleagues, including Navya Nair, MD MPH FACOG FACS, Leslie Randall Róisín O’Cearbhaill, Fernanda Musa,& Drs Einstein and Shuey.

DUO-E improves PFS in women w advanced stage #EndometrialCancer OncoAlert ESGO IGCS astrazeneca.com/media-centre/p…

Celebrating the end of a successful SGO / FdtnForWomensCancer Strategic Meeting Day with Fernanda Musa KD Richardson Amanda Nickles Fader, MD Mark Lauren Prescott #SGOMtg

Up and at ‘em with an early morning Chicago running tour - SGO style with Lauren Prescott Barbara Goff Stephanie Blank Fernanda Musa Kickstarting our discussion of FdtnForWomensCancer Strategic Planning #SGOMtg

🙌 Really exciting data presented by Dr. Moore on DB-1303- this #HER2 #AntibodyDrugConjugate demonstrated 44% response rate in heavily pre-treated patients! #ASCO23 #gyncsm

LBA Kathleen Moore: MIRASOL Practice changing! Confirms SORAYA. Mirvetuximab new SOC in folate receptor alpha platinum-resistant ovarian cancer! #ASCO23 #gyncsm

👀this is the FIRST TRIAL to show overall survival benefit in platinum resistant #OvarianCancer. 🙌Standard of care is clear! 🧐Get the FOLR1 testing and identify the patients that will benefit from mirvetuximab #ASCO23 #gyncsm

SGO member Fernanda Musa featured in the The Seattle Times seattletimes.com/seattle-news/h…

votervoice.net/mobile/SGO/Cam…